Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/4024
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | - |
dc.contributor.author | SPENCER, S. K. M. | - |
dc.contributor.author | POMMIER, A. J. C. | - |
dc.contributor.author | MORGAN, S. R. | - |
dc.contributor.author | BARRY, S. T. | - |
dc.contributor.author | ROBERTSON, J. D. | - |
dc.contributor.author | HOFF, P. M. | - |
dc.contributor.author | JUERGENSMEIER, J. M. | - |
dc.date.accessioned | 2014-01-28T22:20:07Z | - |
dc.date.available | 2014-01-28T22:20:07Z | - |
dc.date.issued | 2013 | - |
dc.identifier.citation | BRITISH JOURNAL OF CANCER, v.109, n.11, p.2765-2773, 2013 | - |
dc.identifier.issn | 0007-0920 | - |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/4024 | - |
dc.description.abstract | Background: The prognostic and predictive value of multiple serum biomarkers was evaluated using samples from a randomised phase III study (HORIZON II) investigating chemotherapy with or without cediranib in metastatic colorectal cancer (mCRC). Methods: Baseline levels of 207 protein markers were measured in serum samples from 582 HORIZON II (FOLFOX/XELOX plus cediranib 20 mg (n = 330) or placebo (n = 252)) patients. Median baseline values of each biomarker were used to categorise patients as high or low. Markers were then assessed for their association with efficacy, defined by progression-free survival (PFS) and overall survival (OS). A generalised boosted regression model identified markers of particular interest. Results: Correlation of protein levels with PFS and OS suggested that multiple factors had a prognostic value, independent of treatment arm, including IL-6, IL-8, C-reactive protein (CRP), ICAM-1 and carcinoembryonic antigen (CEA). Among the angiogenesis regulators, low levels of vascular endothelial growth factor (VEGF), VEGF-D, VEGFR-1, VEGFR-3, NRP1 and Tie-2 correlated with better outcome. Conclusion: This large data set generated using serum samples from mCRC patients treated with chemotherapy and VEGF inhibitors, defines baseline characteristics for 207 serum proteins. Multiple prognostic factors were identified that could be disease related or predict which patients derive most benefit from 5-fluorouracil (5-FU)-based chemotherapy, meriting further exploration in prospective studies. | - |
dc.description.sponsorship | AstraZeneca | - |
dc.description.sponsorship | Initial Training Network TranSVIR grant | - |
dc.language.iso | eng | - |
dc.publisher | NATURE PUBLISHING GROUP | - |
dc.relation.ispartof | British Journal of Cancer | - |
dc.rights | restrictedAccess | - |
dc.subject | cediranib | - |
dc.subject | biomarker | - |
dc.subject | prognostic/predictive marker | - |
dc.subject | colorectal cancer | - |
dc.subject | FOLFOX/XELOX | - |
dc.subject.other | endothelial growth-factor | - |
dc.subject.other | randomized phase-iii | - |
dc.subject.other | double-blind | - |
dc.subject.other | bevacizumab | - |
dc.subject.other | oxaliplatin | - |
dc.subject.other | combination | - |
dc.subject.other | inhibitor | - |
dc.subject.other | azd2171 | - |
dc.subject.other | trials | - |
dc.title | Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy | - |
dc.type | article | - |
dc.rights.holder | Copyright NATURE PUBLISHING GROUP | - |
dc.identifier.doi | 10.1038/bjc.2013.649 | - |
dc.identifier.pmid | 24149180 | - |
dc.subject.wos | Oncology | - |
dc.type.category | original article | - |
dc.type.version | publishedVersion | - |
hcfmusp.author.external | SPENCER, S. K. M.:AstaZeneca, Clin Oncol, Macclesfield, Cheshire, England | - |
hcfmusp.author.external | POMMIER, A. J. C.:AstaZeneca, Translat Sci, Oncol, Macclesfield, Cheshire, England | - |
hcfmusp.author.external | MORGAN, S. R.:AstaZeneca, Clin Oncol, Macclesfield, Cheshire, England | - |
hcfmusp.author.external | BARRY, S. T.:AstaZeneca, Translat Sci, Oncol, Macclesfield, Cheshire, England | - |
hcfmusp.author.external | ROBERTSON, J. D.:AstaZeneca, Clin Oncol, Macclesfield, Cheshire, England | - |
hcfmusp.author.external | JUERGENSMEIER, J. M.:AstaZeneca, Translat Sci, Oncol, Macclesfield, Cheshire, England | - |
hcfmusp.description.beginpage | 2765 | - |
hcfmusp.description.endpage | 2773 | - |
hcfmusp.description.issue | 11 | - |
hcfmusp.description.volume | 109 | - |
hcfmusp.origem | WOS | - |
hcfmusp.origem.id | WOS:000327762700002 | - |
hcfmusp.origem.id | 2-s2.0-84888863037 | - |
hcfmusp.publisher.city | LONDON | - |
hcfmusp.publisher.country | ENGLAND | - |
hcfmusp.relation.reference | Chen E, 2009, CLIN CANCER RES, V15, P1481, DOI 10.1158/1078-0432.CCR-08-0761 | - |
hcfmusp.relation.reference | Drevs J, 2007, J CLIN ONCOL, V25, P3045, DOI 10.1200/JCO.2006.07.2066 | - |
hcfmusp.relation.reference | Friedman JH, 2001, ANN STAT, V29, P1189, DOI 10.1214/aos/1013203451 | - |
hcfmusp.relation.reference | Goldberg Richard M, 2004, Clin Colorectal Cancer, V4 Suppl 1, pS9, DOI 10.3816/CCC.2004.s.002 | - |
hcfmusp.relation.reference | Hegde PS, 2013, CLIN CANCER RES, V19, P929, DOI 10.1158/1078-0432.CCR-12-2535 | - |
hcfmusp.relation.reference | Hoff PM, 2012, J CLIN ONCOL, V30, P3596, DOI 10.1200/JCO.2012.42.6031 | - |
hcfmusp.relation.reference | Jurgensmeier JM, 2013, BRIT J CANCER, V108, P1316, DOI 10.1038/bjc.2013.79 | - |
hcfmusp.relation.reference | Kopetz S, 2010, J CLIN ONCOL, V28, P453, DOI 10.1200/JCO.2009.24.8252 | - |
hcfmusp.relation.reference | Liu Yingmiao, 2013, Cancer Med, V2, P234, DOI 10.1002/cam4.71 | - |
hcfmusp.relation.reference | Ridgeway G., 2007, GEN BOOSTED MODELS G | - |
hcfmusp.relation.reference | Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930 | - |
hcfmusp.relation.reference | Schmoll HJ, 2012, J CLIN ONCOL, V30, P3588, DOI 10.1200/JCO.2012.42.5355 | - |
hcfmusp.relation.reference | Tran HT, 2012, LANCET ONCOL, V13, P827, DOI 10.1016/S1470-2045(12)70241-3 | - |
hcfmusp.relation.reference | Wedge SR, 2005, CANCER RES, V65, P4389, DOI 10.1158/0008-5472.CAN-04-4409 | - |
dc.description.index | MEDLINE | - |
hcfmusp.remissive.sponsorship | AstraZeneca | - |
hcfmusp.citation.scopus | 23 | - |
hcfmusp.scopus.lastupdate | 2024-04-12 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/MDR Artigos e Materiais de Revistas Científicas - HC/InRad Artigos e Materiais de Revistas Científicas - LIM/24 Artigos e Materiais de Revistas Científicas - ODS/03 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_SPENCER_Prognostic_predictive_value_of_207_serum_factors_in_2013.PDF Restricted Access | publishedVersion (English) | 2.07 MB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.